AstraZeneca explores potential transaction with Acerta
Add BT as a preferred sourcePublished Mon, Dec 14, 2015 · 08:31 AM
DeeperDive is a beta AI feature. Refer to full articles for the facts.
[PARIS] AstraZeneca Plc said it's exploring potential strategic options with Acerta Pharma BV, a maker of cancer medicines.
There can be no certainty that a "transaction will ultimately be entered into, or as to the terms of any transaction," the London-based company said in a statement.
BLOOMBERG
Share with us your feedback on BT's products and services
TRENDING NOW
From 1MDB to ‘corporate mafia’: Is Malaysia facing a new governance test?
Middle East-linked energy supply shocks put Asean Power Grid back in focus
Beijing’s calculated silence on the Iran war
DPM Gan warns of 3 structural shifts to the global system that will bring greater challenges – and opportunities
